Alport syndrome from bench to bedside: the potential of current treatment beyond RAAS blockade and the horizon of future therapies (Q38244117)

31 August 2017

Alport syndrome from bench to bedside: the potential of current treatment beyond RAAS blockade and the horizon of future therapies (English)

1 reference

31 August 2017

1 reference

3

1 reference

31 August 2017

Oliver Gross

1

1 reference

PubMed ID

25165179

31 August 2017

Laura Perin

series ordinal

2

1 reference

PubMed ID

25165179

31 August 2017

language of work or name

English

0 references

publication date

1 September 2014

1 reference

Nephrology Dialysis Transplantation

31 August 2017

1 reference

31 August 2017

29 Suppl 4

1 reference

31 August 2017

iv124-30

1 reference

Alport's syndrome, Goodpasture's syndrome, and type IV collagen.

31 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU028

Isoform switching of type IV collagen is developmentally arrested in X-linked Alport syndrome leading to increased susceptibility of renal basement membranes to endoproteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU028

Laminin-1 reexpression in Alport mouse glomerular basement membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU028

Cellular origins of type IV collagen networks in developing glomeruli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU028

Meta-analysis of genotype-phenotype correlation in X-linked Alport syndrome: impact on clinical counselling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU028

Integrin alpha1beta1 and transforming growth factor-beta1 play distinct roles in alport glomerular pathogenesis and serve as dual targets for metabolic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU028

Loss of collagen-receptor DDR1 delays renal fibrosis in hereditary type IV collagen disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU028

An update on the pathomechanisms and future therapies of Alport syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU028

Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU028

Diagnosis of Alport syndrome--search for proteomic biomarkers in body fluids

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU028

21 January 2018

Collagens at a glance

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU028

A lethal variant of osteogenesis imperfecta has a single base mutation that substitutes cysteine for glycine 904 of the alpha 1(I) chain of type I procollagen. The asymptomatic mother has an unidentified mutation producing an overmodified and unstab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU028

Therapeutic approaches to repair defects in deltaF508 CFTR folding and cellular targeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU028

Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU028

Laminin β2 gene missense mutation produces endoplasmic reticulum stress in podocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU028

Chemical chaperone treatment reduces intracellular accumulation of mutant collagen IV and ameliorates the cellular phenotype of a COL4A2 mutation that causes haemorrhagic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU028

Evidence for activation of the unfolded protein response in collagen IV nephropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU028

Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU028

Stem cell therapies benefit Alport syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU028

Bone marrow-derived cells contribute to podocyte regeneration and amelioration of renal disease in a mouse model of Alport syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU028

Regenerative medicine of the kidney.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU028

Injection of amniotic fluid stem cells delays progression of renal fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU028

Mesenchymal stem cells in kidney inflammation and repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU028

Macrophages in renal development, injury, and repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU028

Wnt4-transformed mouse embryonic stem cells differentiate into renal tubular cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU028

Cells differentiated from mouse embryonic stem cells via embryoid bodies express renal marker molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU028

In vitro differentiation of murine embryonic stem cells toward a renal lineage

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU028

Direct transcriptional reprogramming of adult cells to embryonic nephron progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU028

Monitoring and robust induction of nephrogenic intermediate mesoderm from human pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU028

The directed differentiation of human iPS cells into kidney podocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU028

A novel source of cultured podocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU028

Nephrin missense mutations: induction of endoplasmic reticulum stress and cell surface rescue by reduction in chaperone interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU028

MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU028

TGFβ-stimulated microRNA-21 utilizes PTEN to orchestrate AKT/mTORC1 signaling for mesangial cell hypertrophy and matrix expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU028

HEREDITARY FAMILIAL CONGENITAL HAEMORRHAGIC NEPHRITIS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU028

Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU028

Outcomes of male patients with Alport syndrome undergoing renal replacement therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU028

Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU028

Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU028

21 January 2018

Identifiers

DOI

10.1093/NDT/GFU028

1 reference

31 August 2017

1 reference

PubMed ID

25165179